CYTOPROTECTIVE THERAPY POTENTIAL IN PATIENTS WITH CHRONIC COR PULMONALE
The study investigated effectiveness and safety of a cytoprotector mexicor in patients with chronic cor pulmonale (CCP). All participants (n=56; age 38-80 years) were divided into four groups. Group I (n=16) received a standard pulmonary therapy, while Group II (n=20) also received mexicor (300 mg/d...
Main Authors: | S. A. Surotkina, A. A. Kotlyarov, N. M. Selezneva, E. N. Efremova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«FIRMA «SILICEA» LLC
2010-10-01
|
Series: | Российский кардиологический журнал |
Subjects: | |
Online Access: | https://russjcardiol.elpub.ru/jour/article/view/1495 |
Similar Items
-
CHARACTERISTICS OF COMBINED USE OF MEXICOR TOGETHER WITH SOME ANTIARRHYTHMIC DRUGS IN ACUTE OCCLUSION OF CORONARY ARTERY IN EXPERIMENTAL STUDY
by: A. A. Kotljarov, et al.
Published: (2003-10-01) -
MEXICOR EFFECTIVENESS IN PATIENTS WITH BRADYARRHYTHMIAS
by: A. A. Kotlyarov, et al.
Published: (2009-06-01) -
MEXICOR EFFECTIVENESS IN PATIENTS WITH CHRONIC HEART FAILURE AND METABOLIC SYNDROME
by: M. E. Statsenko, et al.
Published: (2009-12-01) -
Yakton and mexicor influence on the indicators of glycolysis, glyconeogenesis and energoproduct function of mitochondria in the rats’ myocardium in the conditions of doxorubicin cardiomyopathy
by: E. A. Raketskaya, et al.
Published: (2015-08-01) -
MEXICOR IN THE COMBINATION THERAPY OF CHRONIC HEART FAILURE AND TYPE 2 DIABETES MELLITUS
by: M. E. Statsenko, et al.
Published: (2011-12-01)